Get the Stockscreener App
0.92
2.64%
-0.0249
After Hours:
.92
PainReform Ltd stock is currently priced at $0.92, with a 24-hour trading volume of 24,562.
It has seen a -2.64% decreased in the last 24 hours and a -46.82% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.9422 pivot point. If it approaches the $0.9149 support level, significant changes may occur.
Previous Close:
$0.9449
Open:
$0.9449
24h Volume:
24,562
Market Cap:
$2.28M
Revenue:
-
Net Income/Loss:
$-9.34M
P/E Ratio:
-0.1013
EPS:
-9.0833
Net Cash Flow:
$-6.69M
1W Performance:
+9.63%
1M Performance:
-46.82%
6M Performance:
-58.56%
1Y Performance:
+48.39%
1D Range:
$0.8708
$0.95
52W Range:
$0.4171
$26.41
PainReform Ltd Stock (PRFX) Company Profile
Name
PainReform Ltd
Sector
Phone
972 3 717 7050
Address
65 Yigal Alon Street, Tel Aviv
PainReform Ltd Stock (PRFX) Latest News
PainReform Announces Closing of $4 Million Public Offering
GlobeNewswire Inc.
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
GlobeNewswire Inc.
PainReform Provides Year-End Business Update
GlobeNewswire Inc.
PainReform Ltd Stock (PRFX) Financials Data
PainReform Ltd (PRFX) Net Income 2024
PRFX net income (TTM) was -$9.34 million for the quarter ending December 31, 2023, a -6.28% decrease year-over-year.
PainReform Ltd (PRFX) Cash Flow 2024
PRFX recorded a free cash flow (TTM) of -$6.69 million for the quarter ending December 31, 2023, a -3.45% decrease year-over-year.
PainReform Ltd (PRFX) Earnings per Share 2024
PRFX earnings per share (TTM) was -$7.14 for the quarter ending December 31, 2023, a +12.18% growth year-over-year.
About PainReform Ltd
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
2.43%
3.29%
Cap:
|
Volume (24h):